利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.032 秒)

    Reverse emulsion aliphatic alkylation process with catalyst-olefin premixing
    1.
    发明授权
    Reverse emulsion aliphatic alkylation process with catalyst-olefin premixing 失效
    反相乳液脂肪族烷基化方法与催化烯烃预混合

    公开(公告)号：US5969206A

    公开(公告)日：1999-10-19

    申请号：US785041

    申请日：1997-01-17

    申请人： Jacques Alagy ,  Jean-Francois Joly ,  Eric Benazzi ,  Jean-Charles Viltard ,  Luis Borges ,  Alain Forestiere

    发明人： Jacques Alagy ,  Jean-Francois Joly ,  Eric Benazzi ,  Jean-Charles Viltard ,  Luis Borges ,  Alain Forestiere

    IPC分类号： C07C2/76 ,  C07B61/00 ,  C07C2/62 ,  C07C9/16 ,  C07C9/21 ,  C10G35/06 ,  C10G35/10 ,  C07C2/58

    CPC分类号： C07C2/62 ,  C07C2527/054 ,  C07C2527/1206

    摘要： The invention concerns a process for the alkylation of at least one isoaffin selected from the group formed by isobutane and isopentane by at least one olefin containing 2 to 6 carbon atoms per molecule in the presence of a liquid acid catalyst, the process comprising mixing a feed comprising the olefin to be converted with an effluent comprising a major portion of isoparaffin in a first mixing zone, and forming an emulsion of said catalyst in a hydrocarbon effluent comprising a major portion of isoparaffin in an emulsifying zone, said effluent constituting the continuous phase of the emulsion thus formed, then mixing a major portion of the emulsion of acid in hydrocarbon effluent with a major portion of the diluted feed comprising the olefin in a second mixing zone, followed by carrying out the majority of the reaction in a reaction zone which is supplied by the major portion of said mixture.

    摘要翻译： 本发明涉及在液体酸催化剂存在下，通过至少一种含有2-6个碳原子的烯烃在异丁烷和异戊烷中形成的至少一种异构烷烃的烷基化方法，该方法包括混合进料 包括在第一混合区域中用包含大部分异链烷烃的流出物转化的烯烃，并且在包含乳化区中的主要部分异链烷烃的烃流出液中形成所述催化剂的乳液，所述流出物构成连续相 由此形成的乳液，然后将大部分酸性乳液在烃流出物中与主要部分的稀释进料在第二混合区中混合，然后在反应区中进行大部分反应，反应区是 由所述混合物的主要部分供应。

    Modulation of lir function to treat rheumatoid arthritis
    3.
    发明申请
    Modulation of lir function to treat rheumatoid arthritis 审中-公开
    调节lir功能治疗类风湿关节炎

    公开(公告)号：US20050238643A1

    公开(公告)日：2005-10-27

    申请号：US10495695

    申请日：2002-11-12

    申请人： Jonathan Arm ,  Nicodemus Tedla ,  Luis Borges

    发明人： Jonathan Arm ,  Nicodemus Tedla ,  Luis Borges

    IPC分类号： A61K45/00 ,  A61K39/395 ,  A61K45/06 ,  A61P29/00 ,  A61P43/00 ,  C07K16/28

    CPC分类号： C07K16/2803 ,  A61K2039/505

    摘要： This invention relates to methods for treating rheumatoid arthritis (RA) by administering one or more agents that specifically target LIR-2, LIR-3 and LIR-7. Results disclosed herein indicate that these three LIRs may participate in regulating the activation of leukocytes that infiltrate synovial tissue. Thus, inflammation in the joints of RA patients can be ameliorated by administering agents that modulate expression or function of LIR-2 and/or LIR-3 and/or LIR-7 to reduce or eliminate the activation of monocytes or macrophages present in inflamed joints, or to reduce their recruitment to the site of inflammation. This can be accomplished by modulating LIR-7, which transmits a stimulatory signal, and/or by modulating LIR-2 and/or LIR-3, which when triggered exert an inhibitory effect, or by concurrently modulating two or all three of these LIRs.

    摘要翻译： 本发明涉及通过施用一种或多种特异性靶向LIR-2，LIR-3和LIR-7的试剂来治疗类风湿性关节炎（RA）的方法。 本文公开的结果表明，这三种LIR可参与调节渗透滑膜组织的白细胞的活化。 因此，RA患者关节炎症可以通过调节LIR-2和/或LIR-3和/或LIR-7的表达或功能的给药剂来改善，以减少或消除发炎关节中存在的单核细胞或巨噬细胞的活化 ，或减少他们招募到炎症部位。 这可以通过调节传递刺激信号的LIR-7和/或通过调节LIR-2和/或LIR-3来实现，其在触发时发挥抑制作用，或通过同时调节这些LIR中的两个或所有三个 。